65th ASH Annual Meeting & Exposition: 905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology

Symposia: Outcomes Research—Lymphoid Malignancies Oral and Poster Abstracts
Oral

Research, Lymphoid Leukemias, ALL, Clinical Practice (Health Services and Quality), CLL, Clinical Research, health outcomes research, health disparities research, Diversity, Equity, and Inclusion (DEI) , patient-reported outcomes, Diseases, real-world evidence, Therapies, Lymphoid Malignancies, Adverse Events, survivorship

San Diego Ballroom AB (Marriott Marquis San Diego Marina)

Moderators:

Melissa A. Acquazzino, MD, ARRAY(0x1055ad54) and Raul Cordoba, MD, PhD, Fundación Jiménez Díaz University Hospital

Disclosures:

Cordoba: Fundacion Jimenez Diaz University Hospital: Current Employment; F. Hoffmann-La Roche Ltd, Takeda, Abbvie, Janssen, AstraZeneca, Lilly, BeiGene, BMS, Genmab, Incyte, Gilead: Consultancy; F. Hoffmann-La Roche Ltd, Takeda, Abbvie, Janssen, AstraZeneca, Lilly, BeiGene, BMS, Genmab, Incyte, Gilead: Speakers Bureau; European Hematology Association (EHA), Spanish Society Hematology (SEHH): Membership on an entity's Board of Directors or advisory committees.

In this session we will other factors which may have impact in the outcome and survival of patients with leukemia beyond biology and genetics. Transformed disease and comorbidities such as cardiovascular diseases will have a negative impact in the final outcome. Disparities and Patient-Reported Outcome Measurement (PROM) will play a role in the outcome of patients with this type of hematological malignancy.

9:30 AM

493

Racial/Ethnic Disparity for Hematologic Malignancies in Different Healthcare Systems in the U.S

Rockbum Kim¹, Emily Zhou²^*, Kaitlin N Swinnerton³^*, Danielle Guffey⁴^*, Shengling Ma, MD⁵, Raka Bandyo⁶^*, Arash Maghsoudi⁷^*, Omar Rosales⁸^*, Abiodun O. Ouyomi⁸^*, Nhan V Do, MD^3,9^*, Mary T Brophy, MD^3,9^*, Jennifer La, PhD³^*, Nathanael R Fillmore, PhD^3,10^* and Ang Li, MD, MS¹

¹Section of Hematology-Oncology, Department of Medicine, Baylor College of Medicine, Houston, TX
²McGovern Medical School, University of Texas Health Science Center, Houston, TX
³Massachusetts Veterans Epidemiology Research and Information Center, VA Boston Healthcare System, Boston, MA
⁴Institute for Clinical & Translational Research, Baylor College of Medicine, Houston, TX
⁵Section of Hematology-Oncology, Baylor College of Medicine, HOUSTON, TX
⁶Harris Health System, Houston, TX
⁷Health Services Research Department of Medicine, Baylor College of Medicine, Houston, TX
⁸Section of Epidemiology and Population Sciences, Department of Medicine, Baylor College of Medicine, Houston, TX
⁹Boston University School of Medicine, Boston, MA
¹⁰Harvard Medical School, Boston, MA

9:45 AM

494

Disparities in Phase 3 Leukemia Trials from the Last Decade: A Long Way to Go

Andres Noyola-Perez¹, Alejandra J. Osuna-Corrales²^*, Manali I. Patel, MD MPH MS³^*, Jorge Cortes, MD⁴, Lillian Sung, MD, PhD⁵, Juan C. Angulo-Lozano, MD⁶^*, Perla R. Colunga-Pedraza, MD⁷, David Gomez-Almaguer, MD⁸, Guillermo José Ruiz-Arguelles, FRCP⁹ and Andres Gomez-De Leon, MD⁸

¹Hematology Department, Universidad Autonoma de Nuevo Leon (UANL). Facultad de Medicina y Hospital Universitario “Dr. José Eleuterio González”, Monterrey, Mexico
²Hematology Deparment, Universidad Autonoma de Nuevo Leon, Monterrey, Mexico
³Oncology Department, Stanford University School of Medicine, Stanford, CA
⁴Georgia Cancer Center, Augusta University, Augusta, GA
⁵The Hospital for Sick Children, Toronto, ON, Canada
⁶Laboratory of Molecular Genetics and Immunology, Rockefeller University, New York City, NY
⁷Servicio de Hematología, Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
⁸Universidad Autónoma de Nuevo León, Facultad de Medicina y Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Mexico, Monterrey, Mexico
⁹Centro De Hematologia Medicina Interna, Puebla, Pue, Mexico

10:00 AM

495

Risk Factors for CD19-Targeting CAR T Manufacturing Failure and Patient Outcomes: A Report from the UK National CAR T Panel

Vaishali Dulobdas¹^*, Amy A Kirkwood²^*, Fabio Serpenti, MD³^*, Brijesh Gautama⁴^*, Aikaterini Panopoulou⁵^*, Sumantha Gabriel⁶^*, Ram Malladi, PhD⁷^*, Jessica Pealing⁸^*, Denise Bonney⁹^*, Emma Nicholson, MD, PhD¹⁰^*, Caroline Besley, MD¹¹^*, Sara Ghorashian¹²^*, Elizabeth Davies¹³^*, Jackie Chappell¹⁴^*, Anne Black¹⁵^*, Tobias Menne, PhD¹⁶^*, Maeve O'Reilly⁵^*, Robin Sanderson¹⁷ and Sridhar Chaganti, MD, PhD, FRCPath, MRCP¹^*

¹Centre for Clinical Haematology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
²Cancer Research UK & UCL Cancer Trials Centre, UCL Cancer Institute, University College London, London, United Kingdom
³King’s College Hospital NHS Foundation Trust, London, United Kingdom
⁴Department of Pharmacy, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
⁵Department of Haematology, University College London Hospitals, London, United Kingdom
⁶Pharmacy Department, Northern Centre for Cancer Care - The Newcastle Upon Tyne NHS Hospitals Foundation Trust, Newcastle, United Kingdom
⁷Department of Haematology, Addenbrooke’s Hospital, Cambridge, United Kingdom
⁸Department of Pharmacy, The Christie Hospital, Manchester, United Kingdom
⁹Department of Paediatric Haematology, Manchester University NHS Foundation Trust, Manchester, United Kingdom
¹⁰Department of Haematology, Royal Marsden Hospital, London, United Kingdom
¹¹Department of Haematology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, United Kingdom
¹²Great Ormond Street Hospital For Children, University College London, London, United Kingdom
¹³Manchester University NHS Foundation Trust, Manchester, United Kingdom
¹⁴Pharmacy Department, King's College Hospital NHS Foundation Trust, London, United Kingdom
¹⁵NHS Specialist Pharmacy Service, Newcastle, United Kingdom
¹⁶Newcastle Upon Tyne NHS Hospitals Foundation Trust, Newcastle, United Kingdom
¹⁷Department of Haematology, King’s College Hospital NHS Foundation Trust, London, United Kingdom

10:15 AM

496

Pre-Existing Cardiovascular Disease Increases the Risk of Cardiovascular Adverse Events during Bruton Tyrosine Kinase Inhibitor Therapy

Maria J. Fernandez Turizo¹, Eunice Kim, PharmD²^*, Aarti Asnani, MD³^*, Tuyen Yankama, MPH⁴^*, Gottfried Von Keudell, MD, PhD⁵ and Caroline Mejías-De Jesús, PharmD, BCOP²^*

¹Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
²Department of Pharmacy, Beth Israel Deaconess Medical Center, Boston, MA
³Cardio-Oncology Section, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
⁴Department of Biostatistics and Data Analytics, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
⁵Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

10:30 AM

497

Outcomes of Patients with Richter Transformation without Prior Chemoimmunotherapy for CLL/SLL: An International Multicenter Retrospective Study

Adam S Kittai, MD¹, Ying Huang, MS, MA¹, Sarah Miller, BS²^*, John N. Allan, MD³, Seema A Bhat, MD¹, David A. Bond, MD, BS⁴, Danielle M Brander, MD⁵, John C. Byrd, MD⁶, Julio C Chavez, MD⁷, Elise A. Chong, MD⁸, Matthew S. Davids, MD, MMSc⁹, Alexey Danilov, MD¹⁰, Wei Ding, MD, PhD¹¹, Mark R Dowling, MBBS, PhD¹²^*, Kaitlyn M. Dvorak-Kornaus, PhD¹^*, Hannah Freedman, RN⁹^*, Paul J Hampel, MD¹¹, Carrie I Ho, MD¹³, Steven R Hwang, MD¹¹, Prioty Islam, MD¹⁴^*, Nitin Jain, MD¹⁵, Matthew Matasar, MD, MS¹⁶, Cecelia Miller, PhD¹⁷^*, Erin M Parry, MD, PhD⁹, Kari G. Rabe, MS¹⁸^*, Manoj Rai, MD¹⁹^*, Phil Raess, MD, PhD²⁰^*, Lindsey E. Roeker, MD¹⁴, Joanna M. Rhodes, MD²¹, Kerry A Rogers, MD¹, Aditi Saha, MBBS²², Jake Schade, BA¹⁶^*, Hamish S Scott, PhD, BSc¹², Mazyar Shadman, MD, MPH¹³, Geoffrey P. Shouse, PhD, DO²³, Alan Skarbnik, MD²⁴, Stephen E Spurgeon, MD²⁵, Deborah M. Stephens, DO²⁶, Meghan C. Thompson, MD¹⁴, Philip A. Thompson, MBBS²⁷^*, Yucai Wang, MD, PhD¹¹, William G. Wierda, MD, PhD²⁸, Max Yano, MD, PhD²⁹^*, Omer Zulfa, MD⁶^* and Jennifer A. Woyach, MD¹

¹Division of Hematology, The Ohio State University, Columbus, OH
²Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH
³Weill Cornell Medicine, Long Island City, NY
⁴The James Cancer Center, The Ohio State University Wexner Medical Center, Columbus, OH
⁵Duke Cancer Center, Durham, NC
⁶Department of Internal Medicine, University of Cincinnati, Cincinnati, OH
⁷Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁸Abramson Cancer Center, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA
⁹Department of Medical Oncology, Harvard Medical School, Dana-Farber Cancer Institute, Boston, MA
¹⁰City of Hope National Medical Center, Duarte, CA
¹¹Division of Hematology, Mayo Clinic, Rochester, MN
¹²Peter MacCallum Cancer Centre, Department of Clinical Haematology, Royal Melbourne Hospital, Melbourne, Australia
¹³Division of Medical Oncology, University of Washington, Seattle, WA
¹⁴Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
¹⁶Division of Blood Disorders, Rutgers Cancer Institute, New Brunswick, NJ
¹⁷Division of Pathology, The Ohio State University, Galena, OH
¹⁸Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
¹⁹Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health and Sciences University, Portland, OR
²⁰Department of Pathology and Laboratory Medicine, Oregon Health & Science University, Portland, OR
²¹Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
²²Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL
²³Hematology/HCT, City of Hope National Medical Center, Duarte, CA
²⁴Lymphoma and CLL/SLL Program, Novant Health Cancer Institute, Charlotte, NC
²⁵Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR
²⁶Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
²⁷Peter MacCallum Cancer Center, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia
²⁸The University of Texas MD Anderson Cancer Center, Houston, TX
²⁹College of Medicine, The Ohio State University, Columbus, OH

10:45 AM

498

Longitudinal Analysis of Patient Reported Quality of Life in Newly Diagnosed Chronic Lymphocytic Leukemia Stratified By Initial Management Strategy: A Multi-Institutional Prospective Cohort Study

Amber Koehler, PA-C¹^*, Brie N. Noble, MS²^*, Timothy G. Call, MD³, Sameer A. Parikh, MD⁴, Tait D. Shanafelt, MD⁵, Mazie Tsang, MD⁶, Côme Bommier, MD, MSc⁷^*, Kari G. Rabe, MS⁸^*, Christopher Strouse, MD⁹, Carrie Thompson, MD, MS³, Paul J. Hampel, MD¹, Kathleen Yost, PhD¹⁰^*, Melissa C. Larson, MS⁷^*, Susan L. Slager, PhD¹¹, Brian K. Link, MD¹²^*, James R. Cerhan, MD, PhD¹¹ and Amylou Constance Dueck, PhD²

¹Mayo Clinic, Rochester, MN
²Mayo Clinic, Scottsdale, AZ
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN
⁵Department of Medicine, Division of Hematology, Stanford University, Stanford, CA
⁶Hematology/Oncology, UCSF, Phoenix, AZ
⁷Division of Epidemiology, Mayo Clinic, Rochester, MN
⁸Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN
⁹Division of Hematology, Oncology and Blood & Marrow Transplantation, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA
¹⁰Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
¹¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN
¹²University of Iowa, Iowa City, IA

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

905A.O2.6 905. Outcomes Research – Lymphoid Malignancies: Factors That Affect Outcomes in Patients With Leukemia-Beyond the Biology